Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1782 Target Snapshot

Farnesyl pyrophosphate synthase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
555Compounds
182Assays
13Approved Drugs
881.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Farnesyl pyrophosphate synthase shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P14324. Start with osteoporosis, then reuse UniProt P14324 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with osteoporosis, then reuse UniProt P14324 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 5 linked drugs
Open source guide
Disease program
osteoporosis

Farnesyl pyrophosphate synthase shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block. 5 linked drugs remain visible in the same block.

Start review with osteoporosis because it currently carries approved-linked support. Linked drugs include ALENDRONATE SODIUM, IBANDRONATE SODIUM, MINODRONIC ACID, RISEDRONATE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 5 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Farnesyl pyrophosphate synthase as ChEMBL target CHEMBL1782, mapped to UniProt P14324. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Farnesyl pyrophosphate synthase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1782
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P14324
Farnesyl pyrophosphate synthase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Farnesyl pyrophosphate synthase is the right protein anchor across sources, using UniProt P14324 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why osteoporosis is currently framed as approved-linked support. It currently carries 5 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameFarnesyl pyrophosphate synthase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP14324
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelFarnesyl pyrophosphate synthase
UniProt AccessionP14324
Component TypeProtein
Sequence Length419 aa

Farnesyl pyrophosphate synthase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Farnesyl pyrophosphate synthase, mapped to UniProt P14324. Sequence length is 419 aa.

Mapped IDP14324
Review nameFarnesyl pyrophosphate synthase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Farnesyl pyrophosphate synthase shows approved-linked disease relevance led by osteoporosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
osteoporosis
5 linked drugs · 5 direct · 5 efficacy
Linked drugALENDRONATE SODIUM
Linked drugIBANDRONATE SODIUM
Linked drugMINODRONIC ACID
Linked drugRISEDRONATE SODIUM
Approved-linked Approved
postmenopausal osteoporosis
5 linked drugs · 5 direct · 5 efficacy
Linked drugALENDRONATE SODIUM
Linked drugIBANDRONATE SODIUM
Linked drugMINODRONIC ACID
Linked drugRISEDRONATE SODIUM
Approved-linked Approved
breast cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugALENDRONATE SODIUM
Linked drugIBANDRONATE SODIUM
Linked drugPAMIDRONATE DISODIUM
Linked drugZOLEDRONIC ACID
Approved-linked Approved
bone fracture
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBANDRONATE SODIUM
Linked drugZOLEDRONIC ACID
Approved-linked Approved
breast neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBANDRONATE SODIUM
Linked drugZOLEDRONIC ACID
Approved-linked Approved
Hypercalcemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugIBANDRONATE SODIUM
Linked drugZOLEDRONIC ACID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with osteoporosis because it currently carries approved-linked support. Linked drugs include ALENDRONATE SODIUM, IBANDRONATE SODIUM, MINODRONIC ACID, RISEDRONATE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseosteoporosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
2
Phase III
5
Phase II
Assay Mix

Activity Type Distribution

IC50742.0
KI128.0
KD11.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4303669 10.15 Ki 0.07 Approved
CHEMBL4303669 9.62 IC50 0.2399 Approved
CHEMBL923 9.44 IC50 0.36 Approved
CHEMBL923 9.44 Ki 0.36 Approved
CHEMBL100827 9.21 IC50 0.618 Preclinical
CHEMBL434024 9.13 Ki 0.74 Preclinical
CHEMBL408608 9.0 Ki 1.0 Preclinical
CHEMBL56073 8.98 IC50 1.047 Preclinical
CHEMBL301247 8.96 IC50 1.102 Preclinical
CHEMBL55140 8.96 Ki 1.09 Preclinical
Distribution

pChEMBL Value Distribution

84
5.0
98
5.5
159
6.0
131
6.5
86
7.0
64
7.5
40
8.0
23
8.5
5
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

MINODRONIC ACID
CHEMBL319144
Approved 2009
Properties Compare Identifier
ZOLEDRONIC ACID
CHEMBL4303669
Approved 2001
Properties Compare Identifier
ZOLEDRONIC ACID ANHYDROUS
CHEMBL924
Approved 2001
Properties Compare Identifier
RISEDRONIC ACID
CHEMBL923
Approved 1998
Properties Compare Identifier
IBANDRONIC ACID
CHEMBL997
Approved 1996
Properties Compare Identifier
ALENDRONIC ACID
CHEMBL870
Approved 1995
Properties Compare Identifier
ALENDRONATE SODIUM
CHEMBL675
Approved 1995
Properties Compare Identifier
PAMIDRONIC ACID
CHEMBL834
Approved 1991
Properties Compare Identifier
Assay Landscape

Assay Landscape

182
Total Assays
388
Tested Compounds
3
Assay Types
Binding — 177 assays, 388 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 90 204 6.1
assay format 68 149 6.5
cell-based format 19 35 6.7
ADME — 3 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 0 —
Functional — 2 assays, 55 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 55 7.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine